Castle Biosciences (CSTL)
(Real Time Quote from BATS)
$22.54 USD
-0.38 (-1.66%)
Updated Jun 17, 2024 03:24 PM ET
2-Buy of 5 2
D Value C Growth A Momentum C VGM
Earnings News For CSTL
-
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
-
Castle Biosciences Reports First Quarter 2024 Results
-
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
-
Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results
-
Castle Biosciences Reports Third Quarter 2023 Results
-
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
-
Castle Biosciences Reports Second Quarter 2023 Results
-
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline
-
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
-
Castle Biosciences Reports First Quarter 2023 Results
-
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
-
Castle Biosciences Reports Fourth Quarter and Full-Year 2022 Results
-
Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Tops Revenue Estimates
-
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
-
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline
-
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
-
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
-
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q4 Earnings Expected to Decline
-
Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Lags Revenue Estimates
-
Analysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out for
-
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
-
Analysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out for
-
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
-
Analysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out for
-
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates